{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:46:41Z","timestamp":1758970001968,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Postoperative atrial fibrillation (POAF) is one of the most frequent complications after cardiothoracic surgery and a predictor for postoperative mortality and prolonged ICU-stay. Current guidelines suggest the multi-channel inhibitor Vernakalant as a treatment option for rhythm control. However, rare cases of severe hypotension and cardiogenic shock following drug administration have been reported. To elucidate the impact of Vernakalant on hemodynamics, we included ten ICU patients developing POAF after elective cardiac surgery, all of them awake and breathing spontaneously, in this prospective trial. Patients received the recommended dosage of Vernakalant and were clinically observed and monitored (heart rate, invasive blood pressure, pulse oximetry, central venous pressure) in 1-minute-intervals for 20\u2009minutes before- and 120\u2009minutes after the first dose of Vernakalant. The median time from the end of surgery until occurrence of POAF amounted up to 52.8 [45.9\u201377.4] hours, it took 3.5 [1.2\u201310.1] hours from occurrence of POAF until the first application of Vernakalant. All patients received catecholamine support with epinephrine that was held steady and not dynamic throughout the observational phase. We noted stable hemodynamic conditions, with a trend towards a reduction in heart rate throughout the 120\u2009minutes after drug administration. In 7 patients (70%), conversion to sustained sinus rhythm (SR) occurred within 8.0\u2009minutes [6.0\u20139.0]. No serious adverse events (SAEs) were noted during the observation period. In this prospective trial in ICU-patients showing POAF after cardiac surgery, intravenous Vernakalant did not induce clinically relevant negative effects on patients\u2019 hemodynamics but resulted in conversion to sustained SR after a median of 8.0\u2009minutes in 7 out of ten patients.<\/jats:p>","DOI":"10.1038\/s41598-020-64001-8","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T10:03:20Z","timestamp":1587549800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hemodynamic effects of Vernakalant in cardio-surgical ICU-patients treated for recent-onset postoperative atrial fibrillation"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0057-8200","authenticated-orcid":false,"given":"S.","family":"Schnaubelt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Niederd\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6896-7854","authenticated-orcid":false,"given":"C.","family":"Holaubek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Edlinger-Stanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Niessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Steinlechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sulzgruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. O.","family":"Spiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Domanovits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"issue":"3","key":"64001_CR1","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4103\/0971-9784.69047","volume":"13","author":"SG Nair","year":"2010","unstructured":"Nair, S. G. Atrial fibrillation after cardiac surgery. Ann Card Anaesth. 13(3), 196\u2013205 (2010).","journal-title":"Ann Card Anaesth."},{"key":"64001_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1749-8090-7-87","volume":"7","author":"S Helgadottir","year":"2012","unstructured":"Helgadottir, S., Sigurdsson, M. I., Ingvarsdottir, I. L., Arnar, D. O. & Gudbjartsson, T. Atrial fibrillation following cardiac surgery: risk analysis and long-term survival. J Cardiothorac Surg. 7, 87 (2012).","journal-title":"J Cardiothorac Surg."},{"doi-asserted-by":"crossref","unstructured":"Batra, G., et alA.B.L.A.J. Atrial fibrillation in patients undergoing coronary artery surgery is associated with adverse outcome. Ups J Med Sci, 1\u20138 (2018).","key":"64001_CR3","DOI":"10.1080\/03009734.2018.1504148"},{"issue":"38","key":"64001_CR4","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof, P. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 37(38), 2893\u2013962 (2016).","journal-title":"Eur Heart J."},{"key":"64001_CR5","doi-asserted-by":"publisher","first-page":"203179","DOI":"10.5402\/2011\/203179","volume":"2011","author":"C Chelazzi","year":"2011","unstructured":"Chelazzi, C., Villa, G. & Gaudio, A. R. Postoperative atrial fibrillation. ISRN Cardiol 2011, 203179 (2011).","journal-title":"ISRN Cardiol"},{"issue":"4","key":"64001_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/187152512803530306","volume":"10","author":"C Rostagno","year":"2012","unstructured":"Rostagno, C. Atrial fibrillation in patients undergoing surgical revascularization: an update on pharmacologic prophylaxis. Cardiovasc Hematol Agents Med Chem 10(4), 325\u201338 (2012).","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"64001_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijcard.2015.03.122","volume":"185","author":"AV Ganapathy","year":"2015","unstructured":"Ganapathy, A. V., Monjazeb, S., Ganapathy, K. S., Shanoon, F. & Razavi, M. \u201cAsymptomatic\u201d persistent or permanent atrial fibrillation: A misnomer in selected patients. Int J Cardiol 185, 112\u20133 (2015).","journal-title":"Int J Cardiol"},{"issue":"5","key":"64001_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehu476","volume":"36","author":"E Aliot","year":"2015","unstructured":"Aliot, E. et al. The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial. Eur Heart J 36(5), 255\u20136 (2015).","journal-title":"Eur Heart J"},{"issue":"8","key":"64001_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jacc.2007.10.043","volume":"51","author":"N Echahidi","year":"2008","unstructured":"Echahidi, N., Pibarot, P., O\u2019Hara, G. & Mathieu, P. Mechanisms, Prevention, and Treatment of Atrial Fibrillation After Cardiac Surgery. Journal of the American College of Cardiology 51(8), 793\u2013801 (2008).","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"64001_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCEP.111.968305","volume":"5","author":"A Burashnikov","year":"2012","unstructured":"Burashnikov, A., Pourrier, M., Gibson, J. K., Lynch, J. J. & Antzelevitch, C. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circ Arrhythm Electrophysiol 5(2), 400\u20138 (2012).","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"12","key":"64001_CR11","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1177\/0091270011426876","volume":"52","author":"F Buccelletti","year":"2012","unstructured":"Buccelletti, F. et al. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis. J Clin Pharmacol 52(12), 1872\u20138 (2012).","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"64001_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/CIRCEP.109.870204","volume":"2","author":"PR Kowey","year":"2009","unstructured":"Kowey, P. R. et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2(6), 652\u20139 (2009).","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"6","key":"64001_CR13","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.ejcts.2006.09.003","volume":"30","author":"J Dunning","year":"2006","unstructured":"Dunning, J., Treasure, T., Versteegh, M. & Nashef, S. A. M. Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 30(6), 852\u201372 (2006).","journal-title":"Eur J Cardiothorac Surg"},{"key":"64001_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12872-016-0289-0","volume":"16","author":"GN Beatch","year":"2016","unstructured":"Beatch, G. N. & Mangal, B. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial. BMC Cardiovasc Disord 16, 113 (2016).","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"64001_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijcard.2013.08.139","volume":"169","author":"D Conde","year":"2013","unstructured":"Conde, D. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation? Int J Cardiol 169(2), 95\u20136 (2013).","journal-title":"Int J Cardiol"},{"key":"64001_CR16","first-page":"309","volume":"4","author":"AJ Camm","year":"2010","unstructured":"Camm, A. J. The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the USA? Curr Cardiol Rev 4, 309\u201314 (2010).","journal-title":"Curr Cardiol Rev"},{"issue":"11","key":"64001_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jchf.2017.06.013","volume":"5","author":"JJ Hsu","year":"2017","unstructured":"Hsu, J. J., Ziaeian, B. & Fonarow, G. C. Heart failure with mig-range (borderline) ejection fraction: Clinical implications and future directions. JACC Heart Fail 5(11), 763\u2013771 (2017).","journal-title":"JACC Heart Fail"},{"issue":"6","key":"64001_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/europace\/eur416","volume":"14","author":"AJ Camm","year":"2012","unstructured":"Camm, A. J. et al. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. Europace 14(6), 804\u20139 (2012).","journal-title":"Europace"},{"issue":"2","key":"64001_CR19","first-page":"233","volume":"19","author":"A Simon","year":"2017","unstructured":"Simon, A. et al. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. Europace 19(2), 233\u201340 (2017).","journal-title":"Europace"},{"unstructured":"Cardiome UK Limited. Brinavess: EPAR-Product Information. Accessed July 23, 2012; Available from, https:\/\/www.ema.europa.eu\/documents\/product-information\/brinavess-epar-product-information_en.pdf (2012).","key":"64001_CR20"},{"issue":"7","key":"64001_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/jch.12545","volume":"17","author":"MG Myers","year":"2015","unstructured":"Myers, M. G. & Stergiou, G. S. Should Oscillometric Blood Pressure Monitors Be Used in Patients With Atrial Fibrillation? J Clin Hypertens (Greenwich) 17(7), 565\u20136 (2015).","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"11","key":"64001_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/j.1553-2712.2010.00915.x","volume":"17","author":"IG Stiell","year":"2010","unstructured":"Stiell, I. G. et al. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department. Acad Emerg Med 17(11), 1175\u201382 (2010).","journal-title":"Acad Emerg Med"},{"issue":"3","key":"64001_CR23","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.ijcard.2013.02.006","volume":"168","author":"D Conde","year":"2013","unstructured":"Conde, D. et al. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol 168(3), 2423\u20135 (2013).","journal-title":"Int J Cardiol"},{"key":"64001_CR24","first-page":"826286","volume":"2014","author":"A Rudiger","year":"2014","unstructured":"Rudiger, A., Breitenstein, A., Arrigo, M., Salzberg, S. P. & Bettex, D. Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients. Crit Care Res Pract 2014, 826286 (2014).","journal-title":"Crit Care Res Pract"},{"issue":"1","key":"64001_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/FJC.0b013e3180547553","volume":"50","author":"P Dorian","year":"2007","unstructured":"Dorian, P. et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 50(1), 35\u201340 (2007).","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"64001_CR26","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/europace\/euu014","volume":"16","author":"G Frommeyer","year":"2014","unstructured":"Frommeyer, G. et al. Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization. Europace 16(8), 1240\u20138 (2014).","journal-title":"Europace"},{"issue":"2","key":"64001_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/europace\/eut274","volume":"16","author":"I Savelieva","year":"2014","unstructured":"Savelieva, I., Graydon, R. & Camm, A. J. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Europace 16(2), 162\u201373 (2014).","journal-title":"Europace"},{"issue":"12","key":"64001_CR28","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.107.723866","volume":"117","author":"D Roy","year":"2008","unstructured":"Roy, D. et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117(12), 1518\u201325 (2008).","journal-title":"Circulation"},{"key":"64001_CR29","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3389\/fphys.2017.01052","volume":"8","author":"M Cibis","year":"2017","unstructured":"Cibis, M., Lindahl, T. L., Ebbers, T., Karlsson, L. O. & Carlh\u00e4ll, C. J. Left Atrial 4D Blood Flow Dynamics and Hemostasis following Electrical Cardioversion of Atrial Fibrillation. Front Physiol 8, 1052 (2017).","journal-title":"Front Physiol"},{"issue":"6","key":"64001_CR30","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.chest.2018.03.040","volume":"154","author":"NA Bosch","year":"2018","unstructured":"Bosch, N. A., Cimini, J. & Walkey, A. J. Atrial Fibrillation in the ICU. Chest 154(6), 1424\u20131434 (2018).","journal-title":"Chest"},{"issue":"7","key":"64001_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1540-8167.2011.02280.x","volume":"23","author":"NA Sanders","year":"2012","unstructured":"Sanders, N. A. et al. Restoring sinus rhythm results in blood pressure reduction in patients with persistent atrial fibrillation and a history of hypertension. J Cardiovasc Electrophysiol 23(7), 722\u20136 (2012).","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"6","key":"64001_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MBP.0000000000000211","volume":"21","author":"M Maselli","year":"2016","unstructured":"Maselli, M. et al. Effect of restoring sinus rhythm in hypertensive patients with atrial fibrillation undergoing electrical cardioversion. Blood Press Monit 21(6), 335\u20139 (2016).","journal-title":"Blood Press Monit"},{"issue":"4","key":"64001_CR33","first-page":"297","volume":"108","author":"M Costa","year":"2017","unstructured":"Costa, M. et al. Comparison of Two Central Venous Pressure Control Strategies to Prevent Atrial Fibrillation After Coronary Artery Bypass Grafting. Arq Bras Cardiol 108(4), 297\u2013303 (2017).","journal-title":"Arq Bras Cardiol"},{"issue":"5","key":"64001_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1179\/acb.2006.038","volume":"61","author":"B Massaer","year":"2006","unstructured":"Massaer, B., Bouchez, S. & Poelaer, J. Central venous pressure: an old lady in new clothes? Acta Clin Belg 61(5), 228\u201335 (2006).","journal-title":"Acta Clin Belg"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64001-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64001-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64001-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:29:23Z","timestamp":1670318963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64001-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64001"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64001-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"25 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients treated for AF at the Department of Emergency Medicine, Medical University of Vienna, Austria, have in the past been included in the \u201cSpectrum\u201d registry (Cardiome Pharma Corp.). However, no funding was provided for the current academic study, and there was no influence on study design, -conduction or -interpretation in any way.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6852"}}